Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
109.4 USD | -0.84% | +1.76% | -11.12% |
09:54am | Jazz Pharmaceuticals Q1 Adjusted Earnings Decline, Revenue Rises; Reaffirms 2024 Outlook | MT |
05-01 | (JAZZ) JAZZ PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $18.15 - $19.35 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.12% | 6.88B | |
+29.47% | 699B | |
+25.07% | 571B | |
-4.59% | 364B | |
+17.76% | 326B | |
+3.48% | 286B | |
+14.68% | 236B | |
+4.71% | 198B | |
-12.43% | 194B | |
-3.66% | 154B |
- Stock Market
- Equities
- JAZZ Stock
- News Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals, Zymeworks Enter Into Licensing Deal for HER2-targeted Bispecific Antibody Zanidatamab